REP 160 Pill - blue capsule/oblong
Generic Name: repotrectinib
Pill with imprint REP 160 is Blue, Capsule/Oblong and has been identified as Augtyro 160 mg. It is supplied by Bristol-Myers Squibb Company.
Augtyro is used in the treatment of Non Small Cell Lung Cancer; Solid Tumors and belongs to the drug class multikinase inhibitors. Augtyro 160 mg is not a controlled substance under the Controlled Substances Act (CSA).
Images for REP 160
Augtyro
- Generic Name
- repotrectinib
- Imprint
- REP 160
- Strength
- 160 mg
- Color
- Blue (opaque)
- Shape
- Capsule/Oblong (capsule)
- Availability
- Prescription only
- Drug Class
- Multikinase inhibitors
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- Bristol-Myers Squibb Company
- National Drug Code (NDC)
- 00003-4160
See also:
Opdivo Qvantig
Opdivo Qvantig is used to treat adults with melanoma, non-small cell lung cancer, renal cell ...
Rybrevant
Rybrevant is used to treat certain types of non-small cell lung cancer (NSCLC) in adults. It is ...
Enhertu
Enhertu is a treatment for breast cancer, stomach cancer, and non-small cell lung cancer with HER2 ...
Opdivo
Opdivo is used to treat many cancers, such as melanoma, non-small cell lung cancer, malignant ...
Keytruda
Keytruda is used to treat melanoma, non-small cell lung cancer, malignant pleural mesothelioma ...
Avastin
Avastin is used to brain tumors and cancers of the kidney, colon, rectum, or lung. Learn about side ...
Tagrisso
Tagrisso (osimertinib) may be used to treat adults with non-small cell lung cancer (NSCLC) whose ...
Docetaxel
Docetaxel is used for breast cancer, breast cancer, metastatic, gastric cancer, head and neck ...
Nivolumab
Nivolumab is used to treat melanoma, non-small cell lung cancer, malignant pleural mesothelioma ...
Paclitaxel
Paclitaxel is used for breast cancer, breast cancer, adjuvant, breast cancer, metastatic, kaposi's ...
More about Augtyro (repotrectinib)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: multikinase inhibitors
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.